In patients with melanoma, combination blockade using nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) improved the objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) (12–14), as compared to ipilimumab alone. The gene discussed is CTLA4; the disease is melanoma.